News
Pharmalittle: We’re reading about Sarepta conceding to the FDA, the U.S. transplant system, and more
Sarepta Therapeutics reversed course and agreed to halt all shipments of Elevidys, its gene therapy for Duchenne muscular ...
Sarepta Therapeutics’ Duchenne therapy faces ‘arduous’ path back to market, senior FDA official says
Sarepta Therapeutics faces an "arduous path” to try to get its gene therapy for Duchenne muscular dystrophy back onto the market, a senior FDA official told STAT.
Sarepta will halt all shipments of Elevidys, its drug for Duchenne muscular dystrophy patients, by Tuesday evening.
Officers 'stumbled across' an organised crime group's 'base of operations' believing that the property had been burgled ...
Ozzy Osbourne, the gloomy, demon-invoking lead singer of the pioneering band Black Sabbath who became the throaty, growling ...
For thousands of years sirens have lured sailors, haunted coastlines—and shapeshifted through myth and media. Here's how they ...
Families of missing loved ones face a unique and agonizing grief called ambiguous loss. Experts explain this as the pain of ...
Warning for strong winds and rough seas. Issued by the Natural Hazards Early Warning Centre at 10.00 a.m. on 22 July 2025 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results